180 related articles for article (PubMed ID: 31906676)
1. Interferon-alpha in the treatment of myeloproliferative diseases.
Kissová J
Vnitr Lek; 2019; 65(11):699-703. PubMed ID: 31906676
[TBL] [Abstract][Full Text] [Related]
2. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms.
Stein BL; Tiu RV
J Interferon Cytokine Res; 2013 Apr; 33(4):145-53. PubMed ID: 23570380
[TBL] [Abstract][Full Text] [Related]
3. Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.
Kiladjian JJ; Chomienne C; Fenaux P
Leukemia; 2008 Nov; 22(11):1990-8. PubMed ID: 18843285
[TBL] [Abstract][Full Text] [Related]
4. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
Hasselbalch HC; Holmström MO
Semin Immunopathol; 2019 Jan; 41(1):5-19. PubMed ID: 30203226
[TBL] [Abstract][Full Text] [Related]
5. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.
Jabbour E; Kantarjian H; Cortes J; Thomas D; Garcia-Manero G; Ferrajoli A; Faderl S; Richie MA; Beran M; Giles F; Verstovsek S
Cancer; 2007 Nov; 110(9):2012-8. PubMed ID: 17849460
[TBL] [Abstract][Full Text] [Related]
6. Recombinant interferon alfa in BCR/ABL-negative chronic myeloproliferative neoplasms.
El Bitar S; Arcasoy MO
Clin Adv Hematol Oncol; 2024 Mar; 22(2):80-89. PubMed ID: 38446475
[TBL] [Abstract][Full Text] [Related]
7. Interferon Alpha Has a Strong Anti-tumor Effect in Philadelphia-negative Myeloproliferative Neoplasms.
Mondello P; Di Mirto C; Cuzzocrea S; Arrigo C; Mian M; Pitini V
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e489-e495. PubMed ID: 31231012
[TBL] [Abstract][Full Text] [Related]
8. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives.
Hasselbalch HC; Larsen TS; Riley CH; Jensen MK; Kiladjian JJ
Curr Drug Targets; 2011 Mar; 12(3):392-419. PubMed ID: 21143149
[TBL] [Abstract][Full Text] [Related]
10. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL
Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
[No Abstract] [Full Text] [Related]
11. A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.
Hasselbalch HC
Expert Rev Hematol; 2011 Dec; 4(6):637-55. PubMed ID: 22077528
[TBL] [Abstract][Full Text] [Related]
12. Recommendations for the use of pegylated interferon-α in the treatment of classical myeloproliferative neoplasms.
Forsyth CJ; Chan WH; Grigg AP; Cook NC; Lane SW; Burbury KL; Perkins AC; Ross DM
Intern Med J; 2019 Aug; 49(8):948-954. PubMed ID: 30411442
[TBL] [Abstract][Full Text] [Related]
13. Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone.
Kiladjian JJ; Giraudier S; Cassinat B
Leukemia; 2016 Apr; 30(4):776-81. PubMed ID: 26601783
[TBL] [Abstract][Full Text] [Related]
14. Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients.
Gowin K; Thapaliya P; Samuelson J; Harrison C; Radia D; Andreasson B; Mascarenhas J; Rambaldi A; Barbui T; Rea CJ; Camoriano J; Gentry A; Kiladjian JJ; O'Connell C; Mesa R
Haematologica; 2012 Oct; 97(10):1570-3. PubMed ID: 22419578
[TBL] [Abstract][Full Text] [Related]
15. Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms.
Hansen IO; Sørensen AL; Hasselbalch HC
Eur J Haematol; 2017 Jan; 98(1):75-84. PubMed ID: 27471124
[TBL] [Abstract][Full Text] [Related]
16. Interferons in the treatment of myeloproliferative neoplasms.
Vachhani P; Mascarenhas J; Bose P; Hobbs G; Yacoub A; Palmer JM; Gerds AT; Masarova L; Kuykendall AT; Rampal RK; Mesa R; Verstovsek S
Ther Adv Hematol; 2024; 15():20406207241229588. PubMed ID: 38380373
[TBL] [Abstract][Full Text] [Related]
17. Genetic variation in IL28B (IFNL3) and response to interferon-alpha treatment in myeloproliferative neoplasms.
Lindgren M; Samuelsson J; Nilsson L; Knutsen H; Ghanima W; Westin J; Johansson PL; Andréasson B
Eur J Haematol; 2018 May; 100(5):419-425. PubMed ID: 29369421
[TBL] [Abstract][Full Text] [Related]
18. [Not Available].
Mosca M; Vertenoeil G; Toppaldoddi KR; Plo I; Vainchenker W
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S16-28. PubMed ID: 27494969
[TBL] [Abstract][Full Text] [Related]
19. Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders.
Quintás-Cardama A; Kantarjian HM; Giles F; Verstovsek S
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):409-16. PubMed ID: 16810616
[TBL] [Abstract][Full Text] [Related]
20. Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature.
How J; Hobbs G
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
